X-Chem | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
X-Chem is a leading biotechnology research company specializing in small molecule drug discovery. Utilizing DNA-encoded chemical...
X-Chem is a leading biotechnology research company specializing in small molecule drug discovery. Utilizing DNA-encoded chemical library (DEL) technology, discovery chemistry, and artificial intelligence, X-Chem provides comprehensive solutions for pharmaceutical and biotech companies. With a high success rate in identifying functional hits and a proven track record in various therapeutic targets, X-Chem is dedicated to advancing human health through innovative drug discovery services.
Website
Headquarters
Waltham, MA
Size
201-500 employees
Industry
Biotechnology Research
🛍️ X-Chem Product and Pricing News →
👔 X-Chem CEO, Management and Leadership Team →
⚔️ X-Chem Alternatives and Competitors →
💼 X-Chem Hiring and Layoffs →
🤖 X-Chem Developer, Integration and Automation News →
📈 X-Chem Financials, Fundraising and Valuation News →
🛍️ X-Chem Product and Pricing News
- In 2024, X-Chem advanced drug discovery with 12 peer-reviewed publications and breakthroughs in synthetic chemistry, covalent drug discovery, and DNA-Encoded Library screening.
👔 X-Chem CEO, Management and Leadership Team
⚔️ X-Chem Alternatives and Competitors
- KBP Biosciences |
- 10xBio |
- TRIM-edicine |
- Astex Pharmaceuticals |
- Icagen |
- TorreyPines Therapeutics |
- Arrakis Therapeutics |
- Atomwise |
- Enveda Biosciences |
- Exscientia |
- Black Diamond Therapeutics |
- Frontier Medicines |
- Nurix Therapeutics |
- Nimbus Therapeutics |
- 1859 |
- Syngens AS |
- STRmix |
- Ventus Therapeutics |
- Editas Medicine |
- Domainex |
- PhenoVista Biosciences |
- Horizon Discovery |
- Active Biotech
💼 X-Chem Hiring and Layoffs
- Waseem Abbas has left X-Chem as a Machine Learning Engineer in the United Kingdom to join GSK as a Software Engineer AI/ML.
🤖 X-Chem Developer, Integration and Automation News
- X-Chem is collaborating with Tonix Pharma on the development of the antiviral drug TNX-4200 under a Department of Defense contract worth up to $34 million.